Single-enantiomer drugs represent an increasingly large share of new chemical entities, leading to approaches in asymmetric synthesis.
Paul H. Moran
Advertisement
Paul H. Moran, PhD, is a research specialist at Chirotech Technology Ltd.
Articles by Paul H. Moran
Advertisement
Latest Updated Articles
Manufacture of Asymmetric Hydrogenation CatalystsPublished: October 4th 2007 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Everything to Know About Pharmaceutical Tariffs in 2025
2
Behind the Headlines Episode 28: Navigating FDA Shakeups and Obesity Drug Wars
3
New Dosage Forms and Delivery Systems Driving 505(b)(2) Success
4
Challenges for the Global Manufacturing of Vaccines
5
